These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
113 related articles for article (PubMed ID: 21894048)
21. Biomarkers and efficacy: are we nearly there yet? Russo A; Rizzo S Ann Oncol; 2011 Jul; 22(7):1469-1470. PubMed ID: 21551003 [No Abstract] [Full Text] [Related]
22. New biomarkers and targets in pancreatic cancer and their application to treatment. Costello E; Greenhalf W; Neoptolemos JP Nat Rev Gastroenterol Hepatol; 2012 Aug; 9(8):435-44. PubMed ID: 22733351 [TBL] [Abstract][Full Text] [Related]
23. Clinical significance of GNAS mutation in intraductal papillary mucinous neoplasm of the pancreas with concomitant pancreatic ductal adenocarcinoma. Ideno N; Ohtsuka T; Matsunaga T; Kimura H; Watanabe Y; Tamura K; Aso T; Aishima S; Miyasaka Y; Ohuchida K; Ueda J; Takahata S; Oda Y; Mizumoto K; Tanaka M Pancreas; 2015 Mar; 44(2):311-20. PubMed ID: 25479586 [TBL] [Abstract][Full Text] [Related]
24. Genetic and epigenetic markers in the evaluation of pancreatic masses. Ginestà MM; Mora J; Mayor R; Farré A; Peinado MA; Busquets J; Serrano T; Capellá G; Fabregat J J Clin Pathol; 2013 Mar; 66(3):192-7. PubMed ID: 23135349 [TBL] [Abstract][Full Text] [Related]
26. Discordance of KRAS mutational status in a single colonic resection specimen in a patient with colorectal cancer: a case report and review of the literature. Smaglo BG; Marshall JL Clin Colorectal Cancer; 2013 Sep; 12(3):214-7. PubMed ID: 23755925 [No Abstract] [Full Text] [Related]
27. Usefulness of p16 and K-ras mutation in pancreatic adenocarcinoma and chronic pancreatitis differential diagnosis. Talar-Wojnarowska R; Gasiorowska A; Smolarz B; Romanowicz-Makowska H; Strzelczyk J; Janiak A; Kulig A; Malecka-Panas E J Physiol Pharmacol; 2004 Jul; 55 Suppl 2():129-38. PubMed ID: 15608367 [TBL] [Abstract][Full Text] [Related]
28. KRAS mutations in advanced nonsquamous non-small-cell lung cancer patients treated with first-line platinum-based chemotherapy have no predictive value. Mellema WW; Dingemans AM; Thunnissen E; Snijders PJ; Derks J; Heideman DA; Van Suylen R; Smit EF J Thorac Oncol; 2013 Sep; 8(9):1190-5. PubMed ID: 23787801 [TBL] [Abstract][Full Text] [Related]
29. Autophagy, p53, and pancreatic cancer. Iacobuzio-Donahue CA; Herman JM N Engl J Med; 2014 Apr; 370(14):1352-3. PubMed ID: 24693896 [No Abstract] [Full Text] [Related]
30. Managing advanced colorectal cancer: have we reached the PEAK with current therapies? Wolpin BM; Bass AJ J Clin Oncol; 2014 Jul; 32(21):2200-2. PubMed ID: 24934780 [No Abstract] [Full Text] [Related]
31. Ribonucleoprotein HNRNPA2B1 interacts with and regulates oncogenic KRAS in pancreatic ductal adenocarcinoma cells. Barceló C; Etchin J; Mansour MR; Sanda T; Ginesta MM; Sanchez-Arévalo Lobo VJ; Real FX; Capellà G; Estanyol JM; Jaumot M; Look AT; Agell N Gastroenterology; 2014 Oct; 147(4):882-892.e8. PubMed ID: 24998203 [TBL] [Abstract][Full Text] [Related]
32. The association between the expression of solute carrier transporters and the prognosis of pancreatic cancer. Mohelnikova-Duchonova B; Brynychova V; Hlavac V; Kocik M; Oliverius M; Hlavsa J; Honsova E; Mazanec J; Kala Z; Melichar B; Soucek P Cancer Chemother Pharmacol; 2013 Sep; 72(3):669-82. PubMed ID: 23934321 [TBL] [Abstract][Full Text] [Related]
33. Activation-Induced Cytidine Deaminase Contributes to Pancreatic Tumorigenesis by Inducing Tumor-Related Gene Mutations. Sawai Y; Kodama Y; Shimizu T; Ota Y; Maruno T; Eso Y; Kurita A; Shiokawa M; Tsuji Y; Uza N; Matsumoto Y; Masui T; Uemoto S; Marusawa H; Chiba T Cancer Res; 2015 Aug; 75(16):3292-301. PubMed ID: 26113087 [TBL] [Abstract][Full Text] [Related]
34. MicroRNA-206 functions as a pleiotropic modulator of cell proliferation, invasion and lymphangiogenesis in pancreatic adenocarcinoma by targeting ANXA2 and KRAS genes. Keklikoglou I; Hosaka K; Bender C; Bott A; Koerner C; Mitra D; Will R; Woerner A; Muenstermann E; Wilhelm H; Cao Y; Wiemann S Oncogene; 2015 Sep; 34(37):4867-78. PubMed ID: 25500542 [TBL] [Abstract][Full Text] [Related]
35. KRAS in pancreatic cancer. Agarwal A; Saif MW JOP; 2014 Jul; 15(4):303-5. PubMed ID: 25076326 [TBL] [Abstract][Full Text] [Related]
36. Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy. Collisson EA; Sadanandam A; Olson P; Gibb WJ; Truitt M; Gu S; Cooc J; Weinkle J; Kim GE; Jakkula L; Feiler HS; Ko AH; Olshen AB; Danenberg KL; Tempero MA; Spellman PT; Hanahan D; Gray JW Nat Med; 2011 Apr; 17(4):500-3. PubMed ID: 21460848 [TBL] [Abstract][Full Text] [Related]
37. The added value of using mutational profiling in addition to cytology in diagnosing aggressive pancreaticobiliary disease: review of clinical cases at a single center. Malhotra N; Jackson SA; Freed LL; Styn MA; Sidawy MK; Haddad NG; Finkelstein SD BMC Gastroenterol; 2014 Aug; 14():135. PubMed ID: 25084836 [TBL] [Abstract][Full Text] [Related]
38. [Advance in the biology of pancreatic of cancer]. Buscail L; Bournet B; Dufresne M; Torrisani J; Cordelier P Bull Cancer; 2015 Jun; 102(6 Suppl 1):S53-61. PubMed ID: 26118878 [TBL] [Abstract][Full Text] [Related]
40. [Progress of targeted therapy related to K-ras mutation]. Li ZW; Liu YQ Zhonghua Bing Li Xue Za Zhi; 2012 Jan; 41(1):59-61. PubMed ID: 22455857 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]